Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRI

Hepatocellular Carcinoma Clinical Trial

Official title:

Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRI

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06037343
• Other study ID #: 2023PI111
• Status: Recruiting
• Start date: February 23, 2023
• Est. completion date: October 30, 2023

Study information

• Verified date: September 2023
• Source: Central Hospital, Nancy, France
• Contact: Valérie LAURENT, MD, PhD
• Phone: +33383154181
• Email: v.laurent[@]chru-nancy.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

New algorithms for processing CT acquisitions, based on artificial intelligence, have been reported to improve acquisition quality. Thats' why it's possible to imagine that new scan post-processing algorithms enable better detection and characterization of hepatocellular carcinoma lesions than with standard reconstructions. DLIR reconstructions could even match with MRI detection. The aim of the study is to compare the detection and characterization of hepatic lesions according to the LI-RADS classification in CT with DLIR artificial intelligence reconstruction, compared with ASIR-V reconstruction and the gold standard of MRI.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: October 30, 2023
• Est. primary completion date: February 23, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• undergoing CT and MRI scans in the same week, with protocols dedicated to the detection of HCC lesions

Exclusion Criteria:

• imaging with radiological artefact

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Locations

Country	Name	City	State
France	CHRU de Nancy	Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lesion size in mm		Through study completion, an average of 1 year
Primary	Hypervascular appearance of lesion	Qualitative measurement: presence or absence of hypervascular lesion	Through study completion an average of 1 year
Primary	Hypervascular capsule	Qualitative measurement : presence or absence of hypervascular capsule	Through study completion an average of 1 year
Secondary	Infiltrative nature Classification of the hepatic lesion by LI-RADS in MRI		Through study completion an average of 1 year